Peptide manufacturing is where the commercial GLP-1 era is being decided. The bottleneck shifted in 2024-2025 from API supply (where Bachem, PolyPeptide, CordenPharma, and AmbioPharm collectively expanded multiple sites) to drug product fill-finish and device assembly. Lilly's $4.5B Lebanon Advanced Therapies investment and additional LEAP District commitments, Novo Nordisk's $16.5B Catalent acquisition, and CordenPharma's $200M+ Swiss greenfield plus the $118.96M AmbioPharm Aiken County expansion are sized for the next decade of injectable peptide demand.
Drug product complexity is the new attention point. The June 19, 2026 PharmTech feature emphasized that successful peptide manufacturing in prefilled syringes for high-speed autoinjectors requires a coordinated lifecycle integrating formulation design, Cpk-driven quality control, and factory acceptance testing — increasingly relevant as GLP-1, amylin, and triagonist peptides reach commercial scale. Environmental sustainability is also moving from optional to expected: AusteinPX-led commentary frames early formulation choices as 80% of a drug's environmental impact, and solvent-free fusion-based alternatives are entering practice. PolyPeptide's Vinnova-funded green GLP-1 synthesis project with Red Glead Discovery has demonstrated that DMF-free GLP-1 manufacturing is feasible.
The regulatory layer: the EMA's first-ever synthetic peptide guideline (EMA/CHMP/CVMP/QWP/367182/2025) took effect June 1, 2026, codifying manufacturing-route and impurity expectations across human and veterinary peptide APIs. Stories here cover SPPS capacity, drug product device assembly, green chemistry, and the GLP-1 supply economy. See [[bachem]], [[polypeptide]], [[cordenpharma]], and [[manufacturing]].
WuXi Biologics (HKEX: 2269) announced Sunday August 23, 2026 an agreement to sell its 51.1% stake in Bestchrom, a Shanghai-based supplier of chromatography resins and columns used across peptide and biologic manufacturing, to an undisclosed independent third party. Financial terms of the transaction were not publicly disclosed. Bestchrom's chromatography resins and columns are used across peptide active pharmaceutical ingredient (API) downstream purification (removing impurities from crude peptide product after synthesis) and are part of the broader peptide-CDMO supply chain that supports the GLP-1 and rare-disease peptide manufacturing scale-up. The divestment continues WuXi's strategic portfolio pruning: the company sold its US manufacturing operations to Altaris Capital in January 2025 following the BIOSECURE Act pressures on Chinese biotech companies serving US customers, and sold its vaccine manufacturing business in December 2024. The Bestchrom divestment repositions WuXi around its core antibody, antibody-drug conjugate, and recombinant protein contract manufacturing services. For the broader peptide manufacturing landscape, the Bestchrom transaction adds another data point to the CDMO consolidation and specialization trend that also includes Samsung Biologics' pending $1.8 billion acquisition of PolyPeptide Group (prospectus expected end of August), the Gland Pharma / Neuland Laboratories sterile API partnership in Visakhapatnam, and ongoing capacity build-outs at Bachem, CordenPharma, and AmbioPharm.
Indian drugmaker Mankind Pharma announced Thursday August 20, 2026 the acquisition of exclusive Indian rights to two insulin analogue peptides from Chinese biopharmaceutical firm Chongqing Chenan Biopharmaceutical. Products in scope: insulin degludec (a Novo Nordisk Tresiba equivalent), an ultra-long-acting basal insulin analogue with approximately 42-hour duration of action that provides once-daily basal coverage with reduced nocturnal hypoglycemia compared to insulin glargine; and the insulin degludec plus insulin aspart fixed-combination (Novo Nordisk Ryzodeg equivalent), combining basal and rapid-acting insulin components in a single injection for patients requiring both basal glycemic control and prandial coverage. Financial terms were not disclosed. The agreement strengthens Mankind's diabetes commercial franchise in the world's largest diabetes patient population; India has approximately 101 million adults living with diabetes as of 2023 per International Diabetes Federation estimates, with the burden projected to reach 134 million by 2045. Both molecules are peptides: insulin degludec is a 51-amino-acid peptide analogue with a hexadecanedioic acid attachment at position B29 that enables the ultra-long-acting profile through multi-hexameric self-association at the injection site. The Chinese-Indian licensing structure follows the growing pattern of Chinese biopharmaceutical companies (Chongqing Chenan, Hengrui, Innovent) partnering with regional distribution and manufacturing partners in India, Southeast Asia, and Latin America to scale peptide-based diabetes and metabolic drug access in emerging markets.
The broader peptide contract development and manufacturing organization (CDMO) consolidation wave continues across August 2026 with three concurrent developments. First, Samsung Biologics' pending $1.8 billion all-cash tender offer for PolyPeptide Group AG at CHF 44.31 per share (CHF 1.46 billion total equity value, 40% premium to undisturbed share price) advances toward closing: the formal tender offer prospectus is expected to be published by end of August 2026 following Draupnir Holding B.V. (55.65% stake) commitment to tender and PolyPeptide's Board of Directors unanimous recommendation, with closing expected toward end of 2026. Second, Gland Pharma and Neuland Laboratories announced August 11, 2026 a long-term sterile API manufacturing partnership in Visakhapatnam, India, extending India's growing role as a peptide API manufacturing hub. Third, Bachem, CordenPharma, and AmbioPharm continue capacity build-outs. Collective capacity positioning targets the multi-billion-dollar demand wave from semaglutide and tirzepatide commercial-scale API (roughly $17 billion combined active pharmaceutical ingredient market by 2028 per industry estimates) plus retatrutide, amycretin, VK2735, ribupatide, and next-generation combination peptide Phase 3 programs. The consolidation trajectory suggests peptide CDMO capacity concentration among a smaller number of large operators through the end of the decade, with the Samsung acquisition of PolyPeptide as the anchor transaction.
Samsung Biologics' all-cash tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share (CHF 1.46 billion / $1.8 billion, representing a 40% premium to the undisturbed share price of CHF 31.65) continues to progress. The formal tender offer prospectus is expected to be published by end of August 2026 and will remain open for a minimum of twenty trading days on the SIX Swiss Exchange following a ten trading-day cooling-off period under Swiss takeover law. PolyPeptide's largest individual shareholder Draupnir Holding B.V. (owning approximately 55.65% of shares outstanding) has committed to tender all of its shares into the offer. PolyPeptide's independent Board of Directors unanimously recommends that shareholders accept Samsung Biologics' offer. The transaction would substantially expand Samsung Biologics' peptide CDMO manufacturing footprint beyond its existing antibody and antibody-drug conjugate focus, positioning the combined entity to address the rapidly growing peptide therapeutics demand particularly in obesity and diabetes GLP-1 therapies (Novo Nordisk Wegovy and Ozempic, Eli Lilly Zepbound and Mounjaro), amylin analogs (cagrilintide), and next-generation combination peptide drugs. PolyPeptide operates commercial-scale peptide API manufacturing across the US, Europe, and India. Closing is expected towards the end of 2026 subject to a minimum acceptance threshold of 66⅔% and applicable regulatory approvals.
Lonza (SIX: LONN) reported first-half 2026 earnings Wednesday July 22, 2026: sales of CHF 3.37 billion (up 11.2% at actual exchange rate, up 16.0% at constant exchange rate), CHF 595 million profit (CHF 8.18 per share) versus CHF 426 million (CHF 5.68 per share) in H1 2025, and CHF 1.2 billion core EBITDA (up 27.4% year-over-year) at a 34.8% margin (up 4.4 percentage points). The Advanced Synthesis division, which houses small-molecule and bioconjugate manufacturing, delivered 27.7% CER sales growth driven by demand for small-molecule and bioconjugate products; the Integrated Biologics division grew 10% CER. Lonza lifted its full-year 2026 margin outlook and confirmed CDMO capacity expansion in Stein, Switzerland following a major-pharma ADC clinical and commercial manufacturing agreement. The Lonza H1 print, combined with the July 20 Samsung Biologics $1.8 billion PolyPeptide tender offer and the July 2 Lonza-Nona Biosciences TfR1 BBB deal, sustains the peptide- and biologic-CDMO consolidation thesis that has run through the first half of 2026. Peptide-based GLP-1 manufacturing capacity constraints continue to drive premium CDMO pricing.
Samsung Biologics announced Sunday-Monday July 19-20, 2026 an all-cash public tender offer to acquire Switzerland's PolyPeptide Group for CHF 1.46 billion ($1.8 billion) at CHF 44.31 per share, a 40% premium to the undisturbed share price of CHF 31.65. The transaction represents the largest biopharmaceutical M&A in South Korean history. Strategic rationale: PolyPeptide is a global peptide contract development and manufacturing organization (CDMO) with accelerating revenue growth driven by rising client demand for peptide-based GLP-1 therapies for obesity and diabetes. The acquisition expands Samsung Biologics' capabilities beyond monoclonal antibody manufacturing (its historical strength) into peptide therapeutics and adds PolyPeptide's global network spanning Sweden, Belgium, France, the United States, and India, encompassing R&D, development, and commercial manufacturing capabilities. PolyPeptide's Board of Directors unanimously recommends the offer. The largest shareholder has given an irrevocable tender undertaking representing approximately 55.65% of outstanding shares. Samsung Biologics expects to complete the deal by end of 2026. The deal extends the July 2026 peptide-manufacturing consolidation wave alongside Novartis's $1.5 billion Myricx Bio acquisition (ADC payloads, July 6) and Lonza's Nona Biosciences TfR1 blood-brain-barrier deal (July 2).
Pharmaceutical Technology's June 19, 2026 Weekly Roundup centered on two peptide-manufacturing best-practices features. Ajoy Koppolu argued that successful peptide manufacturing in prefilled syringes for high-speed autoinjectors requires a coordinated lifecycle approach integrating formulation design, Cpk-driven quality control, and factory acceptance testing to ensure consistent, compliant dose delivery — increasingly the bottleneck as injectable GLP-1, amylin, and triple-agonist peptides enter commercial scale. Separately, Elizabeth Hickman (CEO of AusteinPX) argued that early formulation and manufacturing decisions drive up to 80% of a drug's environmental impact, and that solvent-free, fusion-based alternatives to traditional spray-dried dispersion offer simultaneous operational and environmental gains — relevant as PolyPeptide and EMA both pursue greener GLP-1 manufacturing pathways.
AmbioPharm announced June 16 a $118.96 million expansion of its Aiken County, South Carolina headquarters, adding a 68,000-square-foot modular manufacturing building at its existing 1024 Dittman Court campus in North Augusta and creating more than 200 new jobs. The facility will offer commercial-scale GMP synthesis including solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and hybrid approaches, mirroring upgrades made to AmbioPharm's Shanghai facility. Operations target end of 2027. The announcement arrives roughly three weeks after the May 27, 2026 close of CordenPharma's acquisition of AmbioPharm, which secured CordenPharma a second US peptide site (joining Boulder, Colorado) and its first Shanghai-based supply node. AmbioPharm shareholders are reinvesting in the combined entity. The expansion is the largest single US peptide-manufacturing capacity addition of 2026 to date.
Hims & Hers reports Q1 2026 results May 11 after market close. Company guidance: $600–625M revenue (2–7% YoY) and $35–55M adjusted EBITDA (~7% margin), with Q1 carrying a roughly $65M timing impact from the weight-loss shift to 503A fulfillment. Outlook (ex-Eucalyptus) is $2.7–2.9B revenue and $300–375M EBITDA. Hims also launched Testosterone Rx+ — a once-daily pill for low-libido idiopathic hypogonadism — as a non-GLP-1 specialty addition, signaling the wider longevity and peptide play the company has telegraphed for 2026. The California peptide-manufacturing facility acquired in February 2025 sits as a post-PCAC option for producing reclassified Category 1 peptides if the July meeting clears the path.
An investor-facing April 2026 deep dive analyzes Hims & Hers' transformation from compounded GLP-1 distributor to dual-supplier branded telehealth platform after the Novo Nordisk settlement (March 9, 2026), the Eli Lilly partnership expansion (April 23), and the FDA Category 2 peptide reclassification. The piece argues the California peptide manufacturing facility acquired in 2025 — originally for compounded GLP-1s — could pivot to producing reclassified peptides like BPC-157, TB-500, and KPV if July's PCAC clears the path.